NewResearch Grade
Tirzepatide
Dual GIP & GLP-1 receptor agonist
Tirzepatide is a first-in-class dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating both incretin pathways simultaneously, it produces superior effects on glycaemic control, appetite suppression, and body weight reduction compared to single-receptor agonists. It is the active compound in Mounjaro and Zepbound, and represents one of the most clinically significant metabolic research peptides of the decade.
- ✓Dual agonist: GIP & GLP-1 receptors
- ✓Superior weight reduction vs single-receptor agonists
- ✓Potent appetite suppression & satiety signalling
- ✓Improves insulin sensitivity & glucose regulation
- ✓≥99% purity — HPLC verified
Mechanism of Action
Tirzepatide is a dual GIP/GLP-1 receptor agonist delivered as a single synthetic peptide. GIP receptor activation enhances insulin secretion and adipocyte function, while GLP-1 receptor activation suppresses appetite and slows gastric emptying. The combination produces superior glycaemic control and weight reduction compared to GLP-1 monotherapy in clinical research.
For research and educational purposes only. This information is derived from published preclinical and clinical literature and does not constitute medical advice.